Company research
IDEAYA Biosciences, Inc.
CIK 1676725Updated Sep 27, 2026
SecurityIDYA · NASDAQ · equity
IDYA price & chart
Loading TradingView…
NASDAQ:IDYA on TradingView ↗About the company
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. IDEAYA's corporate presentation is available on its website: https://ir.ideayabio.com/.
In the news
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) ↗
Seeking Alpha
Beyond GLP-1 injectables, who wins the next phase for obesity drugs? ↗
IDEAYA Biosciences, Inc. (IDYA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,109,324,000Source | 1,124,091,000Source | 649,316,000Source | 387,969,000Source |
| Property, Plant and Equipment, NetUSD | 8,217,000Source | 8,966,000Source | 6,164,000Source | 6,509,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 112,825,000Source | 84,378,000Source | 157,018,000Source | 68,632,000Source |
| Assets, CurrentUSD | 666,727,000Source | 689,713,000Source | 532,632,000Source | 370,454,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 21,366,000Source | 13,391,000Source | 7,500,000Source | 5,414,000Source |
| Operating Lease, Right-of-Use AssetUSD | 23,068,000Source | 18,775,000Source | 2,246,000Source | 2,484,000Source |
| Other Assets, NoncurrentUSD | — | — | 25,000Source | 99,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 86,390,000Source | 64,944,000Source | 28,226,000Source | 38,514,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 9,000Source | 9,000Source | 7,000Source | 5,000Source |
| Retained Earnings (Accumulated Deficit)USD | -736,539,000Source | -622,841,000Source | -348,364,000Source | -235,403,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 2,267,000Source | 812,000Source | 562,000Source | -2,871,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,022,934,000Source | 1,059,147,000Source | 621,090,000Source | 349,455,000Source |
| Additional Paid in Capital, Common StockUSD | 1,757,197,000Source | 1,681,167,000Source | 968,885,000Source | 587,724,000Source |
| Liabilities and EquityUSD | 1,109,324,000Source | 1,124,091,000Source | 649,316,000Source | 387,969,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 58,815,000Source | 46,071,000Source | 27,101,000Source | 31,718,000Source |
| Operating Lease, Liability, CurrentUSD | 339,000Source | 298,000Source | 1,747,000Source | 1,871,000Source |
| Accounts Payable, CurrentUSD | 17,584,000Source | 15,421,000Source | 6,598,000Source | 4,280,000Source |
| Operating Lease, Liability, NoncurrentUSD | 27,575,000Source | 18,873,000Source | 1,125,000Source | 1,611,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 40,892,000Source | 30,352,000Source | 18,756,000Source | 16,999,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -113,698,000Source | -274,477,000Source | -112,961,000Source | -58,655,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 2,700,000Source | 2,387,000Source | 2,476,000Source | 2,101,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 46,115,000Source | 34,746,000Source | 18,489,000Source | 11,629,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 0Source | -15,000Source | -193,000Source | -892,000Source |
| Increase (Decrease) in Accounts PayableUSD | 2,697,000Source | 8,280,000Source | 2,635,000Source | 1,864,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -71,098,000Source | -247,584,000Source | -115,224,000Source | -87,175,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 69,976,000Source | -502,559,000Source | -158,456,000Source | -33,404,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,368,000Source | 3,857,000Source | 2,368,000Source | 3,443,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 29,779,000Source | 677,551,000Source | 362,717,000Source | 97,165,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 28,657,000Source | -72,592,000Source | 89,037,000Source | -23,414,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 113,840,000Source | 85,183,000Source | 157,775,000Source | 68,738,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 25,000Source | 69,000Source | 60,000Source |
| Income Taxes Paid, NetUSD | — | — | 0Source | 0Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 46,115,000Source | 34,746,000Source | 18,489,000Source | 11,629,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | 0Source |
| General and Administrative ExpenseUSD | 63,319,000Source | 39,302,000Source | 28,306,000Source | 23,897,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -113,698,000Source | -274,477,000Source | -112,961,000Source | -58,655,000Source |
| Nonoperating Income (Expense)USD | 45,615,000Source | 52,498,000Source | 21,468,000Source | 3,847,000Source |
| Operating ExpensesUSD | 378,023,000Source | 333,975,000Source | 157,814,000Source | 113,433,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 1,700,000Source |
| Proceeds from Issuance of Common StockUSD | 0Source | 274,350,000Source | 281,165,000Source | 86,105,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 680,233,000Source | 692,607,000Source | 439,892,000Source | — |
| Proceeds from Stock Options ExercisedUSD | 3,431,000Source | 12,483,000Source | 9,559,000Source | 1,448,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 218,710,000Source | 7,000,000Source | 23,385,000Source | 50,931,000Source |
| Operating Income (Loss)USD | -159,313,000Source | -326,975,000Source | -134,429,000Source | -62,502,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -113,698,000Source | -274,477,000Source | -112,961,000Source | -58,655,000Source |
| Earnings Per Share, BasicUSD per share | -1.28Source | -3.36Source | -1.96Source | -1.42Source |
| Earnings Per Share, DilutedUSD per share | -1.28Source | -3.36Source | -1.96Source | -1.42Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 88,485,238Source | 81,678,069Source | 57,519,929Source | 41,444,696Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 88,485,238Source | 81,678,069Source | 57,519,929Source | 41,444,696Source |
| Additional Financial Items | ||||
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,700,000Source | 2,400,000Source | 2,500,000Source | 2,100,000Source |
| General and Administrative ExpenseUSD | 63,319,000Source | 39,302,000Source | 28,306,000Source | 23,897,000Source |
| Nonoperating Income (Expense)USD | 45,615,000Source | 52,498,000Source | 21,468,000Source | 3,847,000Source |
| Operating ExpensesUSD | 378,023,000Source | 333,975,000Source | 157,814,000Source | 113,433,000Source |
| Operating Lease, ExpenseUSD | — | — | — | 1,700,000Source |
| Research and Development ExpenseUSD | 314,704,000Source | 294,673,000Source | 129,508,000Source | 89,536,000Source |
Filing attachments
idya-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 idya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update • Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion expected in H2 2026 • Updated data from Phase 2 OptimUM-01 trial (HLA*A2-positive mUM patient subset) a…
Read attachment ↗d110954dex41.htm · 8-K · 2026-06-10
EX-4.1 3 d110954dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 IDEAYA BIOSCIENCES, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: [ ], 2026 IDEAYA Biosciences, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is entitled, subject to the…
Read attachment ↗d138848dex991.htm · 8-K · 2026-06-01
EX-99.1 2 d138848dex991.htm EX-99.1 EX-99.1 Darovasertib Plus Crizotinib vs Investigator’s Choice as First-Line Treatment for Patients with HLA-A2 Negative Metastatic Uveal Melanoma: Primary Results from the OptimUM-02 Trial Marlana Orloff,1 Egle Ramelyte,2 Marcus O. Butler,3 Piotr Rutkowski,4 Lorenza Di Guardo,5 Matteo S. Carlino,6 Bartosz Chmielowski,7 Lucy Kennedy,8 Kamaneh Montazeri,9 Joseph Sacco,10 Ernesto Rossi,11 Victoria Atkinson,12 Rizwan Haq,13 Meredith McKean,14 George Cole,15 H…
Read attachment ↗idya-ex99_1.htm · 8-K · 2026-05-05
EX-99.1 2 idya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update • Phase 2/3 registrational trial (OptimUM-02) of darovasertib combination met its primary endpoint; complete data will be provided in a late-breaking oral presentation at ASCO • IDEAYA to initiate RTOR submission process with first pre-submission in May; targeting completion of the NDA filing in H2 2026 • Clinical updates from Phase 2 OptimU…
Read attachment ↗